Uncovering the molecular secrets of inflammatory breast cancer biology

An integrated analysis of three distinct affymetrix gene expression datasets

Steven J. Van Laere, Naoto T. Ueno, Pascal Finetti, Peter Vermeulen, Anthony Lucci, Fredika M. Robertson, Melike Marsan, Takayuki Iwamoto, Savitri Krishnamurthy, Hiroko Masuda, Peter Van Dam, Wendy A. Woodward, Patrice Viens, Massimo Cristofanilli, Daniel Birnbaum, Luc Dirix, James M. Reuben, François Bertucci

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. Experimental Design: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation. Results: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P <0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19% vs. 42%; P <0.001) and the HER2-enriched subtype (22% vs. 9%; P <0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC. Conclusion: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner.

Original languageEnglish
Pages (from-to)4685-4696
Number of pages12
JournalClinical Cancer Research
Volume19
Issue number17
DOIs
Publication statusPublished - Sep 1 2013
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Gene Expression
Breast Neoplasms
Datasets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Uncovering the molecular secrets of inflammatory breast cancer biology : An integrated analysis of three distinct affymetrix gene expression datasets. / Van Laere, Steven J.; Ueno, Naoto T.; Finetti, Pascal; Vermeulen, Peter; Lucci, Anthony; Robertson, Fredika M.; Marsan, Melike; Iwamoto, Takayuki; Krishnamurthy, Savitri; Masuda, Hiroko; Van Dam, Peter; Woodward, Wendy A.; Viens, Patrice; Cristofanilli, Massimo; Birnbaum, Daniel; Dirix, Luc; Reuben, James M.; Bertucci, François.

In: Clinical Cancer Research, Vol. 19, No. 17, 01.09.2013, p. 4685-4696.

Research output: Contribution to journalArticle

Van Laere, SJ, Ueno, NT, Finetti, P, Vermeulen, P, Lucci, A, Robertson, FM, Marsan, M, Iwamoto, T, Krishnamurthy, S, Masuda, H, Van Dam, P, Woodward, WA, Viens, P, Cristofanilli, M, Birnbaum, D, Dirix, L, Reuben, JM & Bertucci, F 2013, 'Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets', Clinical Cancer Research, vol. 19, no. 17, pp. 4685-4696. https://doi.org/10.1158/1078-0432.CCR-12-2549
Van Laere, Steven J. ; Ueno, Naoto T. ; Finetti, Pascal ; Vermeulen, Peter ; Lucci, Anthony ; Robertson, Fredika M. ; Marsan, Melike ; Iwamoto, Takayuki ; Krishnamurthy, Savitri ; Masuda, Hiroko ; Van Dam, Peter ; Woodward, Wendy A. ; Viens, Patrice ; Cristofanilli, Massimo ; Birnbaum, Daniel ; Dirix, Luc ; Reuben, James M. ; Bertucci, François. / Uncovering the molecular secrets of inflammatory breast cancer biology : An integrated analysis of three distinct affymetrix gene expression datasets. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 17. pp. 4685-4696.
@article{bb172395246d4503b5b5ff83b2a8662a,
title = "Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets",
abstract = "Background: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. Experimental Design: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation. Results: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P <0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19{\%} vs. 42{\%}; P <0.001) and the HER2-enriched subtype (22{\%} vs. 9{\%}; P <0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC. Conclusion: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner.",
author = "{Van Laere}, {Steven J.} and Ueno, {Naoto T.} and Pascal Finetti and Peter Vermeulen and Anthony Lucci and Robertson, {Fredika M.} and Melike Marsan and Takayuki Iwamoto and Savitri Krishnamurthy and Hiroko Masuda and {Van Dam}, Peter and Woodward, {Wendy A.} and Patrice Viens and Massimo Cristofanilli and Daniel Birnbaum and Luc Dirix and Reuben, {James M.} and Fran{\cc}ois Bertucci",
year = "2013",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-12-2549",
language = "English",
volume = "19",
pages = "4685--4696",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Uncovering the molecular secrets of inflammatory breast cancer biology

T2 - An integrated analysis of three distinct affymetrix gene expression datasets

AU - Van Laere, Steven J.

AU - Ueno, Naoto T.

AU - Finetti, Pascal

AU - Vermeulen, Peter

AU - Lucci, Anthony

AU - Robertson, Fredika M.

AU - Marsan, Melike

AU - Iwamoto, Takayuki

AU - Krishnamurthy, Savitri

AU - Masuda, Hiroko

AU - Van Dam, Peter

AU - Woodward, Wendy A.

AU - Viens, Patrice

AU - Cristofanilli, Massimo

AU - Birnbaum, Daniel

AU - Dirix, Luc

AU - Reuben, James M.

AU - Bertucci, François

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. Experimental Design: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation. Results: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P <0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19% vs. 42%; P <0.001) and the HER2-enriched subtype (22% vs. 9%; P <0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC. Conclusion: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner.

AB - Background: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. Experimental Design: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation. Results: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P <0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19% vs. 42%; P <0.001) and the HER2-enriched subtype (22% vs. 9%; P <0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC. Conclusion: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner.

UR - http://www.scopus.com/inward/record.url?scp=84883483781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883483781&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2549

DO - 10.1158/1078-0432.CCR-12-2549

M3 - Article

VL - 19

SP - 4685

EP - 4696

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -